Lexicon Pharmaceuticals | LXRX - Ebit


Lexicon Pharmaceuticals reported $-14.78M in EBIT for its fiscal quarter ending in December of 2025.





Ebit Change Date
Abbott USD 1.36B 775M Sep/2026
Acadia Pharmaceuticals USD 71.72M 33.88M Sep/2026
Agios Pharmaceuticals USD -110.55M 527K Jun/2026
Akebia Therapeutics USD -5.45M 9.4M Dec/2025
Alnylam Pharmaceuticals USD 179.66M 67.06M Sep/2026
AstraZeneca USD 4.66B 1.5B Sep/2026
BioMarin Pharmaceutical USD 205.6M 100M Sep/2026
Coherus Biosciences USD -39.08M 3.65M Dec/2025
Eli Lilly USD 13.09B 635M Sep/2026
Halozyme Therapeutics USD -60.68M 3.04M Sep/2026
Illumina USD 305M 45M Sep/2026
Insmed USD -81.83M 19.48M Sep/2026
Ironwood Pharmaceuticals USD 33.22M 7.58M Dec/2024
J&J USD 6.47B 1B Sep/2026
Lexicon Pharmaceuticals USD -14.78M 2.59M Dec/2025
MacroGenics USD -65.25M 33.36M Jun/2026
MannKind USD -59.44M 8.79M Sep/2026
Merck USD 7.33B 6.49B Sep/2026
Moderna USD 130M 945M Sep/2026
Novartis USD 5.14B 411M Sep/2026
PTC Therapeutics USD 146.03M 100.14M Jun/2026
Puma Biotechnology USD -2.2M 11.41M Jun/2024
Sarepta Therapeutics USD -9.04M 22.33M Sep/2026
Thermo Fisher Scientific USD 2.46B 277M Sep/2026
Ultragenyx Pharmaceutical USD -110M 35M Sep/2026
United Therapeutics USD 241.3M 134.3M Sep/2026
Vanda Pharmaceuticals USD -10.28M 721K Dec/2024